Conmed (CNMD) Cash from Financing Activities (2010 - 2026)

Conmed has reported Cash from Financing Activities for 17 years, with the latest figure at -$22.6 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities rose 20.58% year-over-year to -$22.6 million; the trailing twelve-month figure through Mar 2026 stood at -$130.0 million (up 19.96% YoY), and the FY2025 full-year result was -$135.8 million, up 10.05% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at -$22.6 million, up from -$37.4 million in the prior quarter.
• The five-year high for Cash from Financing Activities was $159.1 million in Q2 2022, with the low at -$58.8 million in Q4 2023.
• Historically, Cash from Financing Activities has averaged -$11.5 million across 5 years, with a median of -$26.5 million in 2025.
• Annual changes were most pronounced in 2022 — Cash from Financing Activities soared 820.17% — and 2023, when it slumped 610.34%.
• Conmed's Cash from Financing Activities stood at $11.5 million in 2022, then tumbled by 610.34% to -$58.8 million in 2023, then rose by 13.1% to -$51.1 million in 2024, then climbed by 26.83% to -$37.4 million in 2025, then surged by 39.65% to -$22.6 million in 2026.
• The last three Cash from Financing Activities figures came in at -$22.6 million (Q1 2026), -$37.4 million (Q4 2025), and -$43.5 million (Q3 2025), per Business Quant data.